MedTrace Logo

Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus

NCT02536261 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2017-05-16

No results posted yet for this study

Summary

The purpose of this study is to observe whether dopamine agonists can be safely withdrawn after the tumor volume and prolactin level of invasive prolactinomas involving the cavernous sinus have been effectively controlled through pharmacological treatment.

Conditions

  • Invasive Prolactinomas Involving the Cavernous Sinus

Sponsors & Collaborators

  • Xinqiao Hospital of Chongqing

    collaborator OTHER

  • First Hospital of China Medical University

    collaborator OTHER

  • Beijing Tiantan Hospital

    collaborator OTHER

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • First Affiliated Hospital of Fujian Medical University

    collaborator OTHER

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Huashan Hospital

    collaborator OTHER

  • Zhebao Wu

    lead OTHER

Principal Investigators

  • Zhebao Wu, Medical PhD · Ruijin Hospital

Eligibility

Min Age
15 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02536261 on ClinicalTrials.gov